Literature DB >> 33359714

Rates of RNFL Thinning in Patients with Suspected or Confirmed Glaucoma Receiving Unilateral Intravitreal Injections for Exudative AMD.

Swarup S Swaminathan1, Anne L Kunkler2, Ann V Quan2, Charles M Medert2, Elizabeth A Vanner2, William Feuer2, Ta Chen Chang2.   

Abstract

PURPOSE: This study evaluated whether the rate of retinal nerve fiber layer (RNFL) thinning is faster in eyes receiving intravitreal injections than in fellow uninjected eyes among patients suspected of having or confirmed to have glaucoma and exudative age-related macular degeneration (AMD).
DESIGN: Retrospective comparative cohort study.
METHODS: Patients with a diagnosis of unilateral exudative AMD and confirmed to have or suspected of having glaucoma in both eyes receiving unilateral intravitreal injections were identified. Those with ≥3 RNFL optical coherence tomography scans and ≥6 injections were included in the study. Rates of RNFL thinning in the injected eye versus the uninjected eye were estimated using linear mixed models. The main outcome measurement was the differences in rates of RNFL thinning in the injected versus the fellow uninjected eye. The effects of postinjection elevation of intraocular pressure (IOP), injection frequency, and number of injections were also evaluated.
RESULTS: A total of 53 patients met the inclusion criteria, receiving 26.4 ± 15.9 intravitreal injections. The average rate of RNFL thinning in uninjected eyes was -0.620 μm/year (P = .029). Injected eyes had an additional incremental loss of -0.385 μm/year, but this value was not statistically significant (95% confidence interval [CI]: -1.147 to 0.379 μm/year; P = .324). Subgroup analysis with only glaucoma patients (n = 33) also demonstrated a nonsignificant effect of injections (-0.568 μm/year; 95% CI: -1.454 to 0.319 μm/year; P = .212). Postinjection IOP elevation, injection frequency, and total number of injections were not associated with faster RNFL loss.
CONCLUSIONS: Among exudative AMD patients with glaucoma or suspected of having glaucoma, the rate of RNFL thinning in eyes receiving intravitreal injections did not significantly differ from that of fellow uninjected eyes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33359714      PMCID: PMC8222411          DOI: 10.1016/j.ajo.2020.12.016

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.488


  48 in total

1.  Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study.

Authors:  Güngör Sobacı; Rıza Güngör; Gökhan Ozge
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

2.  Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

Authors:  Robert L Avery; Joel Pearlman; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust; Robert Wendel; Arun Patel
Journal:  Ophthalmology       Date:  2006-10       Impact factor: 12.079

Review 3.  A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab.

Authors:  S R Rufai; H Almuhtaseb; R M Paul; B L Stuart; T Kendrick; H Lee; A J Lotery
Journal:  Eye (Lond)       Date:  2017-05-05       Impact factor: 3.775

4.  Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry.

Authors:  Pierre-Henry Gabrielle; Vuong Nguyen; Benjamin Wolff; Rohan Essex; Stephanie Young; Adrian Hunt; Chui Ming Gemmy Cheung; Jennifer J Arnold; Daniel Barthelmes; Catherine Creuzot-Garcher; Mark Gillies
Journal:  Ophthalmol Retina       Date:  2020-06-20

5.  Rate of Macular Ganglion Cell-inner Plexiform Layer Thinning in Glaucomatous Eyes With Vascular Endothelial Growth Factor Inhibition.

Authors:  Won June Lee; Young Kook Kim; Yong Woo Kim; Jin Wook Jeoung; Seok Hwan Kim; Jang Won Heo; Hyeong Gon Yu; Ki Ho Park
Journal:  J Glaucoma       Date:  2017-11       Impact factor: 2.503

6.  Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration.

Authors:  Rafidah Saleh; Aashraya Karpe; Martin S Zinkernagel; Marion R Munk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-27       Impact factor: 3.117

7.  The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration.

Authors:  Melih Parlak; F Hakan Oner; A Osman Saatci
Journal:  Int Ophthalmol       Date:  2014-07-25       Impact factor: 2.031

8.  Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.

Authors:  Shuang Song; Xiao-Bing Yu; Hong Dai
Journal:  Indian J Ophthalmol       Date:  2016-10       Impact factor: 1.848

9.  Anterior chamber paracentesis during intravitreal injections in observational trials: effectiveness and safety and effects.

Authors:  Sandeep Saxena; Timothy Y Lai; Hideki Koizumi; Michel E Farah; Daniela Ferrara; David Pelayes; Tomohito Sato; Carsten H Meyer; Timothy Murray
Journal:  Int J Retina Vitreous       Date:  2019-03-06

Review 10.  Anti-VEGF Therapy and the Retina: An Update.

Authors:  Vikas Tah; Harry O Orlans; Jonathan Hyer; Edward Casswell; Nizar Din; Vishnu Sri Shanmuganathan; Louise Ramskold; Saruban Pasu
Journal:  J Ophthalmol       Date:  2015-08-31       Impact factor: 1.909

View more
  1 in total

Review 1.  Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short- and Long-term Considerations.

Authors:  Ariana M Levin; Craig J Chaya; Malik Y Kahook; Barbara M Wirostko
Journal:  J Glaucoma       Date:  2021-12-01       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.